Metastatic Transitional (Urothelial) Tract Cancer – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Metastatic Transitional (Urothelial) Tract Cancer – Drugs In Development, 2023’, provides an overview of the Metastatic Transitional (Urothelial) Tract Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Transitional (Urothelial) Tract Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Transitional (Urothelial) Tract Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Transitional (Urothelial) Tract Cancer
- The report reviews pipeline therapeutics for Metastatic Transitional (Urothelial) Tract Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Transitional (Urothelial) Tract Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Transitional (Urothelial) Tract Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Transitional (Urothelial) Tract Cancer
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Transitional (Urothelial) Tract Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Transitional (Urothelial) Tract Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abbisko Therapeutics Co LtdAbbVie Inc
Acrivon Therapeutics Inc
Adaptimmune Therapeutics Plc
Adlai Nortye Biopharma Co Ltd
Akeso Inc
Allorion Therapeutics Inc
Alphamab Oncology
ALX Oncology Holdings Inc
Amgen Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Bicycle Therapeutics Plc
Bio-Thera Solutions Ltd
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
CanWell Pharma Inc
CG Oncology Inc
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chugai Pharmaceutical Co Ltd
CSPC Pharmaceutical Group Ltd
Cullinan Oncology Inc
Daiichi Sankyo Co Ltd
Dyadic International Inc
Ectin Research AB
Eisai Co Ltd
Eli Lilly and Co
Everest Medicines Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Flare Therapeutics Inc
Fujian Cancer Hospital
G1 Therapeutics Inc
Gilead Sciences Inc
Glycotope GmbH
GlyTherix Ltd
GSK plc
Hangzhou DAC Biotech Co Ltd
Hutchison MediPharma Ltd
Ikena Oncology Inc
ImmunityBio Inc
Immutep Ltd
Incyte Corp
Infinity Pharmaceuticals Inc
InnoCare Pharma Ltd
Innovent Biologics Inc
IO Biotech Inc
Jazz Pharmaceuticals Plc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JSR Life Sciences LLC
Karyopharm Therapeutics Inc
KLUS Pharma Inc
Lee's Pharmaceutical Holdings Ltd
Loxo Oncology Inc
Lycera Corp
Mabwell Shanghai Bioscience Co Ltd
MedPacto Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Minghui Pharmaceutical (Shanghai) Co Ltd
Molecular Templates Inc
Myeloid Therapeutics Inc
Nektar Therapeutics
Novartis AG
NuCana Plc
Nurix Therapeutics Inc
Ocellaris Pharma Inc
Orion Biotechnology Canada Ltd
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
PlantForm Corp
Puretech Health Plc
QLSF Biotherapeutics Inc
RemeGen Co Ltd
RevImmune SAS
Salubris Biotherapeutics Inc
Seagen Inc
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai HyaMab Biotech Co Ltd
Shanghai JMT-Bio Technology Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Miracogen Inc
Sichuan Kelun Pharmaceutical Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Systimmune Inc
Taiho Oncology Inc
Totus Medicines Inc
Tyra Biosciences Inc
VasGene Therapeutics Inc
Wuxi Biocity Biopharma Co Ltd
Xuanzhu Biotechnology Co Ltd